Tafinlar-Mekinist Approved for BRAF-Positive Anaplastic Thyroid Cancer

The FDA approved the combination of dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) for the treatment of unresectable or metastatic anaplastic thyroid cancer (ATC) with the BRAF V600E mutation.